GSK Completes Audit Tender, Reappoints Deloitte LLP as External Auditor Through 2028

GSK's Audit Tenure and Auditor Rotation Compliance

As a Public Interest Entity, GSK adheres to strict regulatory mandates requiring a competitive statutory audit tender every 10 years and auditor rotation every 20 years under UK financial reporting and audit regulations. These measures are designed to strengthen auditor independence and uphold financial reporting integrity, common among large UK and EU-listed companies and financial institutions.

Deloitte's engagement with GSK began with the financial year ended 31 December 2018, totaling approximately eight years of service. The decision to reappoint Deloitte after a competitive tender indicates the firm met or surpassed the Audit & Risk Committee's evaluation criteria. Subject to the 20-year rotation rule, Deloitte may continue beyond 2028 if it has not exceeded the maximum tenure.

Deloitte's Role and Tender Process Details

Deloitte has served as GSK's external auditor since the financial year ended 31 December 2018, establishing a nearly decade-long relationship. Their reappointment following the Audit & Risk Committee's competitive tender process reflects confidence in Deloitte's performance, expertise, and audit approach tailored to GSK's complex global biopharma operations.

While the company has not disclosed the number of firms involved or specific selection criteria, further information on the tender process will be available in the 2026 Annual Report. This transparency aligns with best practices in audit committee reporting and governance.

Shareholder Approval at 2028 AGM

The reappointment requires formal shareholder approval at the 2028 Annual General Meeting, consistent with governance standards for Public Interest Entities. Announced in July 2026, this early notification allows shareholders and stakeholders ample time to raise questions ahead of the vote.

The resolution to reappoint Deloitte will be presented approximately 18 months post-announcement, accompanied by detailed tender disclosures in the 2026 Annual Report. This approach exemplifies best practice in audit governance and shareholder engagement, reassuring investors of GSK's commitment to transparent auditor selection.

GSK's Global Biopharma Operations and Audit Requirements

GSK plc operates globally in biopharma, integrating science, technology, and talent to address disease. Its activities span research, development, manufacturing, and commercialization across multiple therapeutic areas and regions. These extensive operations necessitate an auditor with deep expertise in biopharma sector complexities, regulatory compliance, R&D accounting, and multinational tax and treasury issues.

Selecting an auditor for GSK involves evaluating capabilities in clinical trial accounting, regulatory compliance across jurisdictions, intellectual property valuation, and internal controls over manufacturing and quality. Deloitte's continued appointment reflects its proven ability to meet these specialized requirements. GSK's registered office is at 79 New Oxford Street, London WC1A 1DG, registered in England & Wales under number 3888792.

Public Interest Entity Status and Enhanced Audit Governance

As a Public Interest Entity under UK Financial Conduct Authority rules, GSK is subject to enhanced governance, including external audit selection, independence, and reporting standards. These entities include large listed companies and financial institutions whose failure could impact public interest. The mandatory tender and rotation rules safeguard auditor independence by preventing overly familiar auditor-client relationships.

Governance also involves audit committee oversight, pre-approval of audit and non-audit services, and regular shareholder reporting on audit quality. GSK's competitive tender, despite reappointing the incumbent auditor, demonstrates adherence to these principles and active evaluation of alternatives. Public disclosure of the reappointment and forthcoming tender details in the 2026 Annual Report reflect transparency expectations for Public Interest Entities.

Audit Transition Timing and Financial Year Alignment

Deloitte's reappointment will commence with the financial year ending 31 December 2028, allowing the current auditor to complete the 2027 audit. This clear transition boundary facilitates planning for any handover or audit approach changes.

Announcing the reappointment in July 2026, over 18 months before the effective date, aligns with audit planning best practices. This advance notice enables Deloitte to prepare audit strategies, GSK's finance team to anticipate procedural changes, and shareholders to review the proposal thoroughly, minimizing disruption and ensuring continuity.

Future Disclosure in 2026 Annual Report

GSK will provide detailed information on the competitive tender process in its 2026 Annual Report. This will cover participating firms, evaluation criteria, feedback to non-selected candidates, and the Audit & Risk Committee's assessment of Deloitte's capabilities and audit approach. Such disclosure enhances shareholder understanding and demonstrates the committee's diligence.

Including tender details in the annual report is increasingly standard among large listed companies, reflecting growing investor interest in service provider appointments. GSK's commitment to transparency allows shareholders and proxy advisors to evaluate the rigor and independence of the auditor selection ahead of the 2028 AGM.

Regulatory and Compliance Framework for Auditor Selection

GSK's audit tender and reappointment operate within UK corporate law, FCA listing rules, the UK Corporate Governance Code, and International Standards on Auditing. The 10-year tender and 20-year rotation requirements stem from the Statutory Auditors and Third-Country Auditors Regulations, aiming to maintain auditor independence and prevent excessive familiarity. These rules apply to all UK Public Interest Entities and mirror EU audit directives.

The competitive tender, Audit & Risk Committee oversight, and shareholder approval safeguard financial reporting integrity and public confidence. For GSK, with significant regulatory demands from global medicines authorities, a robust external audit is critical. Deloitte's audit supports reliable financial disclosures on pharmaceutical manufacturing standards, clinical trial accounting, and R&D asset valuations.